Pharmaceuticals

Global Lyme Disease Vaccine Industry Insights: Key Trends and Growth Estimates

February 16, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the lyme disease vaccine market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the Lyme Disease Vaccine Market’s size between 2026 and 2030?

The lyme disease vaccine market has demonstrated strong expansion in recent years. It is forecast to increase from $1.12 billion in 2025 to $1.2 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. The growth observed in previous periods stems from factors such as the increasing occurrence of lyme disease in endemic areas, the historical shortcomings of treatment approaches relying solely on antibiotics, initial vaccine research efforts, heightened awareness of tick-borne infections, and improvements in public health surveillance.

The Lyme disease vaccine market is anticipated to show significant expansion over the next few years, with projections indicating it will reach $1.57 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.0%. This forecasted growth can be linked to factors such as the broadening of vaccination initiatives in regions where the disease is prevalent, an uptick in funding for infectious disease prevention, advancements in next-generation vaccine platforms, the increasing acceptance of combination vaccines, and an elevated global focus on controlling zoonotic diseases. Dominant trends expected during this period include improvements in recombinant vaccine technologies, a stronger emphasis on preventive immunization campaigns, an expansion of clinical investigations into tick-borne diseases, a rising demand for solutions offering long-lasting immunity, and increased partnerships between public and private healthcare organizations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=30317&type=smp

Which Drivers Are Shaping Strategic Decisions In The Lyme Disease Vaccine Market?

The rising incidence of Lyme disease is anticipated to drive the expansion of the Lyme disease vaccine market in the future. This tick-borne illness, stemming from Borrelia bacteria, can cause symptoms like fever, tiredness, rashes, and if not addressed, severe issues affecting joints, the heart, or nerves. The growing prevalence of Lyme disease is linked to climate change, where higher temperatures and less severe winters extend the areas ticks inhabit, thereby increasing human contact with infected ticks. Lyme disease vaccines assist in preventing the condition by preparing the immune system to identify and combat Borrelia bacteria, thus lowering infection risks. These vaccines streamline disease control by offering enduring protection and enhancing public health results. For example, in March 2025, data from the Centers for Disease Control and Prevention, a US-based federal health agency, indicated that about 89,000 cases of Lyme disease were reported in the United States in 2023. Additionally, alternative estimation methods suggest that approximately 476,000 people might be diagnosed and treated for Lyme disease annually. Consequently, the increasing prevalence of Lyme disease is a key factor boosting the Lyme disease vaccine market’s growth. The growing financial outlay on healthcare is predicted to boost the expansion of the Lyme disease vaccine market moving ahead. Healthcare expenditure encompasses the overall sum allocated to medical services, treatments, facilities, research, and public health campaigns aimed at maintaining or improving health results. The heightened need for healthcare spending stems from the increasing occurrence of chronic illnesses, which demand prolonged and expensive care. Enhanced healthcare spending facilitates the advancement of Lyme disease vaccines by channeling more funds into research and clinical trials, thereby accelerating innovation and manufacturing. It also backs sophisticated vaccine technologies, making them more accessible and effective for vulnerable groups. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that overall healthcare expenditure saw a 5.6% rise in nominal terms in 2023, representing a 0.9% increase compared to 2022. Consequently, the increasing healthcare expenditure is fueling the growth of the Lyme disease vaccine market.

What Segment Categories Are Covered In The Lyme Disease Vaccine Market?

The lyme disease vaccine market covered in this report is segmented –

1) By Vaccine Type: Recombinant Vaccines, Subunit Vaccines, Live Attenuated Vaccines, Other Vaccine Types

2) By Technology: Lymphocytic Transformation Test, Urine Antigen Testing, Immunofluorescent Staining Nucleic Acid Test, Serological Test

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals And Clinics, Pharmacies, Government Supply, Other Distribution Channels

5) By End User: Hospitals, Clinical Laboratories, Other End Users

Subsegments:

1) By Recombinant Vaccines: Protein-Based Recombinant Vaccines, Vector-Based Recombinant Vaccines, Deoxyribonucleic Acid (DNA)-Based Recombinant Vaccines

2) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines, Conjugate Subunit Vaccines

3) By Live Attenuated Vaccines: Naturally Attenuated Vaccines, Genetically Attenuated Vaccines, Temperature-Sensitive Attenuated Vaccines

4) By Other Vaccine Types: Toxoid Vaccines, Inactivated Vaccines, Vectored Vaccines

Which Market Trends Are Opening Growth Opportunities In The Lyme Disease Vaccine Market?

Leading companies in the Lyme disease vaccine market are concentrating on advancing their late-stage product candidates, such as booster vaccines, to meet existing medical needs, enhance immune defense, and simplify vaccination protocols. Booster vaccines are additional doses administered following initial immunization to restore or improve long-term immunity. For example, in September 2025, Valneva SE, a France-based biotechnology company, confirmed encouraging immunogenicity and safety data from its ongoing Phase 2 study of the Lyme disease vaccine candidate, VLA15. This multivalent vaccine trains the immune system to produce antibodies against OspA proteins on Borrelia bacteria. When a tick bites, these antibodies effectively block the bacteria within the tick, preventing human infection. The strong immune response and favorable safety profile observed after a third booster dose were consistent with those reported after previous annual booster doses, further indicating its compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. This booster strategy is designed to provide continuous protection against Lyme disease, supporting the potential for an annual pre-exposure season booster to simplify protection for at-risk individuals.

Which Major Industry Participants Are Leading The Lyme Disease Vaccine Market Growth?

Major companies operating in the lyme disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Boehringer Ingelheim GmbH, University of Pennsylvania, Elanco Animal Health Incorporated, Zoetis Inc., Emergent BioSolutions Inc., Bavarian Nordic A/S, Aegis Life Inc., Bioveta a.s., Dynavax Technologies Corporation, Valneva SE, MassBiologics of UMass Chan Medical School, Inovio Pharmaceuticals Inc., US Biologic Inc., Blue Lake Biotechnology Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/global-lyme-disease-vaccine-market-report

Which Region Is Expected To Experience The Fastest Growth In The Lyme Disease Vaccine Market?

North America was the largest region in the Lyme disease vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lyme disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Lyme Disease Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=30317&type=smp

Browse Through More Reports Similar to the Global Lyme Disease Vaccine Market 2026, By The Business Research Company

Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Dog Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/dog-vaccines-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795